Abbott Laboratories (ABT) Return on Equity ROE from the first quarter 2026 to first quarter 2025 and annually, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Abbott Laboratories  (NYSE: ABT)

Abbott Laboratories's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Abbott Laboratories in the first quarter 2026?
Abbott Laboratories achieved a return on average equity (ROE) of 12.09 % in its first quarter 2026, which is below Abbott Laboratories's average return on equity, which stands at 17.16%.

ROE decreased relative to the period ending , due to the decline in net income.

Within the Major Pharmaceutical Preparations industry 47 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2025 from 670 to 1190.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Equity Change 7.41 % 10.17 % 28.07 % 28.49 % -
Y / Y Net Income Change -18.72 % -80.76 % -0.12 % 36.64 % 8.16 %
Net Income (TTM) in Millions 6,276 6,524 13,977 13,979 13,502
Return On Equity (TTM) 12.09 % 12.8 % 28.09 % 29.77 % 30.59 %
ABT's Total Ranking # 1190 # 670 # 227 # 214 # 244
Equity (TTM) in Millions 52,701 52,771 51,264 50,829 49,064
Seq. Equity Change -0.13 % 2.94 % 0.86 % 3.6 % 2.43 %
Seq. Net Income Change -39.36 % 8.03 % -7.59 % 34.26 % -85.64 %

Back to ABT Management Effectiveness >> ABT's 5 Years Annual ROE >> Compare ABT ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 48
Sector # 125
Overall # 1190

Return On Equity Statistics
High Average Low
32.19 %
17.16 %
2.14 %
(Dec 31 2024)   (Mar 31 2018)





ABT Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 52,771 47,901 38,827 36,905 36,024
Y / Y Equity Change 10.17 % 23.37 % 5.21 % 2.45 % 9.15 %
Net Income in Millions 6,524 13,402 5,723 6,933 7,071
Y / Y Net Income Change -51.32 % 134.18 % -17.45 % -1.95 % 57.31 %
Return On Equity 12.36 % 27.98 % 14.74 % 18.79 % 19.63 %

Back to ABT Management Effectiveness >> ABT's 5 Years Annual ROE >> Compare ABT ROE to its Competitors




Annual Roe Comment
In 2025 ROE decreased compared to the previous year to 12.36 %, due to deterioration of net income.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ABT's' Return on Equity at Yahoo Finance
ABT's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ABT's Competitors
Subscribers only: Roe for Abbott Laboratories's Suppliers
Subscribers only: Return On Equity for ABT's Customers




Companies with similar Return On Equity at Mar 31 2026, within Healthcare Sector ROE
Rafael Holdings Inc  31.93 %
Solventum Corporation  30.71 %
Phibro Animal Health Corporation  30.60 %
Pro dex Inc   30.01 %
Incyte Corporation  29.20 %
Protalix Biotherapeutics inc   28.10 %
Collegium Pharmaceutical Inc   26.74 %
Pacs Group Inc   26.46 %
Johnson and Johnson  26.26 %
Engene Therapeutics Inc   25.83 %
Encompass Health Corporation  25.56 %
Chemed Corporation  25.33 %
Resmed Inc   24.76 %
Iradimed Corporation  24.48 %
Lantheus Holdings Inc   24.33 %
Prestige Consumer Healthcare Inc   24.20 %
Vertex Pharmaceuticals Inc  23.93 %
Catalyst Pharmaceuticals Inc   23.65 %
Xoma Royalty Corporation  23.64 %
Soleno Therapeutics Inc  22.85 %
Electromed Inc   22.41 %
Iqvia Holdings Inc   22.15 %
Msa Safety Inc  22.03 %
Neurocrine Biosciences Inc   21.64 %
Insulet Corporation  21.38 %
Universal Health Services Inc   21.22 %
Teva Pharmaceutical Industries Limited  20.74 %
Exagen Inc   20.63 %
Sotera Health Company  20.57 %
Puma Biotechnology Inc   20.37 %

Date modified: 2026-09-26T07:14:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.